IMMUNOLOGICAL ABNORMALITIES IN A GROUP OF PATIENTS WITH LIMITED CUTANEOUS SYSTEMIC-SCLEROSIS AND PROMINENT VASCULAR-DISEASE

被引：13

作者：

PASSALEVA, A

MASSAI, G

MATUCCICERINIC, M

DOMENEGHETTI, MP

SHARIFIAN, J

LOTTI, T

CAGNONI, M

RICCI, M

机构：

[1] Cattedra di Allergologia e Immunologia Clinica, University of Florence, 50134, Florence

[2] Patologia Medica I, University of Florence, 50134, Florence

[3] Clinica Dermosifilopatica, University of Florence, 50100, Florence

来源：

AUTOIMMUNITY | 1990年 / 6卷 / 04期

关键词：

Anticardiolipin antibodies; Antinuclear antibodies; Immune complexes; Systemic sclerosis;

D O I：

10.3109/08916939008998420

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antinuclear antibodies, circulating immune complexes, rheumatoid factors and anticardiolipin antibodies were detected in the sera of 17 patients affected by the limited cutaneous subset of systemic sclerosis and marked clinical evidence of ischaemic cutaneous lesions (fingertip ulcerations). This study was designed to evaluate the possible role of anticardiolipin (aCL) antibodies and other immunological disorders in the endothelial damage characteristic of the disease. ACL antibodies were found in 41 % of the patients. With the exception of a significant connection with positive rheumatoid factor tests (RIA), no notable associations between anticardiolipin antibodies and antinuclear antibodies, circulating immune complexes (CIC), and other serological abnormalities were found. ACL antibodies did not significantly correlate with the presence of vascular lesions in our patients. However, a role of these antibodies in endothelial damage cannot be excluded, possibly in association with other serum factors such as immune complexes and antinuclear antibodies. A positive connection between the incidence of CIC and the severity of lung perfusion impairment was observed. and the previously reported relationship between anticentromere antibodies and calcinosis was indirectly confirmed. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：283 / 291

页数：9

共 39 条

[1]

Harris E.N., Syndrome of the black swan, Br J Rheumatol, 26, pp. 324-326, (1987)

[2]

Angles-Cano E., Sultan Y., Clauvel J.P., Predisposing factors to thrombosis in systemic lupus erythema-tosus. Possible relation to endothelial cell damage, J Lab Clin Med, 94, pp. 312-322, (1979)

[3]

Byron M.A., Allington M.J., Chapel H.M., Mowat A.G., Cederholm-Williams S.A., Indication of vascular endothelial cell disfunction in systemic lupus erythematosus, Ann Rheum Dis, 46, pp. 741-745, (1987)

[4]

Carreras L.O., Drefeyn G., Machin S.J., Arterial thrombosis, intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation, Lancet, 1, pp. 244-246, (1981)

[5]

Harris E.N., Asherson R.A., Gharavi A.E., Morgan S.H., Derue G., Hughes G.R.V., Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibodies, Br J Haemathol, 59, pp. 227-230, (1985)

[6]

Khamashta M.A., Harris E.N., Gharavi A.E., Derue G., Gil A., Vazquez J.J., Et al., Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes, Ann Rheum Dis, 47, pp. 849-854, (1988)

[7]

Tuma M.F.F., Missi S.M., Oliveira R.M., Et al., Anticardiolipin antibodies in systemic sclerosis, Clin Exp Rheumatol, 6, (1988)

[8]

Bamberga P., Asero R., Vismara A., Brucato A., Riboldi P., Meroni P.L., Anticardiolipin antibodies in progressive systemic sclerosis (PSS). (Letter), Clin Exp Rheumatol, 5, pp. 387-392, (1987)

[9]

Seibold J.R., Knight P.J., Peter J.B., Anticardiolipin antibodies in systemic sclerosis. (Letter), Arthritis Rheum, 29, pp. 1052-1053, (1986)

[10]

Seibold J.R., Medsger T.A., Winkelstein A., Kelly R.H., Rodnan G.P., Immune complexes in progressive systemic sclerosis (scleroderma), Arthritis Rheum, 25, pp. 1167-1173, (1982)

← 1 2 3 4 →